Experimental drug aims to tame severe COVID-19 inflammation

NCT ID NCT04483973

Completed Disease control Sponsor: Sound Pharmaceuticals, Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests an experimental drug called SPI-1005 (ebselen) in adults hospitalized with severe COVID-19. Participants receive either the drug or a placebo to see if the drug is safe and helps improve recovery. The trial is randomized and double-blind, meaning neither patients nor doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ebselen (SPI-1005)
What this could lead to: If it works, this could point toward a new treatment option for severe COVID-19 that reduces inflammation and speeds recovery.
What could go wrong: This is a small, early-phase trial, so results may not apply broadly. The drug may cause side effects or prove no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 Orthocoronavirinae infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONA VIRUS INFECTION CORONAVIRUS CORONAVIRUS INFECTION COVID19

Contacts and locations

Locations

Duke University

Durham, North Carolina, 27710, United States
Kansas University Medical Center

Kansas City, Kansas, 66160, United States
St. Luke's Cystic Fibrosis Center of Idaho

Boise, Idaho, 83702, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States
Wake Forest University

Winston-Salem, North Carolina, 27109, United States
Washington University in St. Louis

St Louis, Missouri, 63130, United States
Yale University

New Haven, Connecticut, 96510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.